Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis by Nunes, Rute et al.
Journal of Controlled Release 334 (2021) 453–462
Available online 5 May 2021
0168-3659/© 2021 Elsevier B.V. All rights reserved.
Electrospun fibers for vaginal administration of tenofovir disoproxil 
fumarate and emtricitabine in the context of topical 
pre-exposure prophylaxis 
Rute Nunes a,b,c,1, Sarah Bogas d,1, Maria João Faria d, Hugo Gonçalves e, Marlene Lúcio d,f,*, 
Teresa Viseu d, Bruno Sarmento a,b,c, José das Neves a,b,c,** 
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A B S T R A C T   
Women are particularly vulnerable to sexual HIV-1 transmission. Oral pre-exposure prophylaxis (PrEP) with 
tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) is highly effective in avoiding new infections in men, 
but protection has only been shown to be moderate in women. Such differences have been associated, at least 
partially, to poor drug penetration of the lower female genital tract and the need for strict adherence to 
continuous daily oral intake of TDF/FTC. On-demand topical microbicide products could help circumvent these 
limitations. We developed electrospun fibers based on polycaprolactone (PCL fibers) or liposomes associated to 
poly(vinyl alcohol) (liposomes-in-PVA fibers) for the vaginal co-delivery of TDF and FTC, and assessed their 
pharmacokinetics in mice. PCL fibers and liposomes-in-PVA fibers were tested for morphological and physico-
chemical properties using scanning electron microscopy, differential scanning calorimetry and X-ray diffrac-
tometry. Fibers featured organoleptic and mechanical properties compatible with their suitable handling and 
vaginal administration. Fluorescent quenching of mucin in vitro – used as a proxy for mucoadhesion – was intense 
for PCL fibers, but mild for liposomes-in-PVA fibers. Both fibers were shown safe in vitro and able to rapidly 
release drug content (15–30 min) under sink conditions. Liposomes-in-PVA fibers allowed increasing genital drug 
concentrations after a single intravaginal administration when compared to continuous daily treatment for five 
days with 25-times higher oral doses. For instance, the levels of tenofovir and FTC in vaginal lavage were around 
4- and 29-fold higher, respectively. PCL fibers were also superior to oral treatment, although to a minor extent 
(approximately 2-fold higher drug concentrations in lavage). Vaginal tissue drug levels were generally low for all 
treatments, while systemic drug exposure was negligible in the case of fibers. These data suggest that proposed 
fibers may provide an interesting alternative or an ancillary option to oral PrEP in women.   
1. Introduction 
Global incidence of HIV infection remains at unacceptably high 
levels and is unlikely to significantly regress over the next decade [1]. 
Women in particular are largely vulnerable to sexual transmission due to 
various biological, behavioral and socio-demographic factors [2]. 
Protecting women from HIV/AIDS is, therefore, a health imperative. 
Oral pre-exposure prophylaxis (PrEP) emerged over the last decade as an 
effective approach to prevent the sexual transmission of HIV-1. Daily 
oral administration of antiretroviral drugs, namely the combination of 
tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), has been 
shown to be highly efficacious in preventing HIV-1 transmission in men 
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who have sex with men (MSM) [3]. However, outcomes of clinical trials 
involving heterosexual couples have been mixed regarding the efficacy 
of oral PrEP in women [4–7]. Adherence to a daily oral regimen has been 
pointed out as the main cause for failure, but other relevant factors may 
also be involved [8]. For instance, Cottrell et al. [9] showed that poor 
drug penetration of the lower female genital tract – particularly in the 
case of tenofovir (TFV) resulting from the hydrolysis of its prodrug TDF 
by plasma and tissue esterases – may limit the ability of oral PrEP to 
protect women. Furthermore, slow onset of protective drug levels and 
their rapid decline following discontinuation impair the implementation 
of more flexible regimens such as on-demand regimens that have been 
successfully introduced in MSM [10]. Typically, 6–7 consecutive daily 
doses of TDF/FTC are deemed necessary to achieve maximal protection 
in women [11]. Topical PrEP using vaginal microbicides could help 
tackle this limitation of oral TDF/FTC in achieving rapid protective drug 
levels at the genital tract mucosa and potentially allow on-demand use. 
In particular, the vaginal administration of TDF alone [12,13] or in 
combination with FTC [14,15] was able to effectively prevent infection 
in animal models. 
Engineering suitable drug delivery platforms is a key step in the 
microbicide development process. Electrospun polymeric fibers have 
been proposed for vaginal drug delivery, particularly in the context of 
HIV-1 prevention, contraception and sexual health [16]. These systems 
are easy to produce at both the laboratory and industrial scales and are 
highly versatile. For instance, fibers can simultaneously incorporate 
different active compounds and be engineered to modulate drug release 
by using different materials or by changing their architecture [17–19]. 
Fiber mats can be used similarly to commercially available vaginal films, 
presenting advantages such as the possibility of self-administration 
without the need of an applicator, avoidance of extensive leakage 
typical of semisolid products, or minimal interference with sexual in-
tercourse [20]. Preclinical data suggest that fibers allow achieving quick 
and extensive coverage of the vaginal epithelium, which could be crucial 
for providing effective protection from HIV-1 transmission [21]. 
Furthermore, an exploratory study conducted by performing focus 
group interviews found that fiber mats are likely to be well accepted by 
women for topical PrEP [22]. 
We hypothesize that vaginal TDF/FTC-loaded fibers may be inter-
esting systems for on-demand topical PrEP. Two types of electrospun 
formulations, each loaded with both drugs and comprising either hy-
drophobic polycaprolactone (PCL) fibers or a composite of liposomes 
and hydrophilic poly(vinyl alcohol) (PVA) fibers, were developed. In the 
case of the composite, we attempted to explore liposomes not only for 
the purpose of retaining TDF and FTC in fibers, but also for taking 
advantage of the possible capacity of nanocarriers to improve microbi-
cide drug distribution and retention in the vagina [23]. Both types of 
fibers were evaluated regarding the ability to provide potentially pro-
tective vaginal drug levels, namely by comparing single-dose pharma-
cokinetics (PK) of fibers to that of continuous use of oral PrEP with TDF/ 
FTC in a murine model. 
2. Materials and methods 
2.1. Materials 
TDF was purchased from Kemprotec (Cumbria, UK) and FTC from 
Sequoia Research Products (Pangbourne, UK). TFV was kindly supplied 
by Gilead Sciences (Foster City, CA, USA). PCL (80 kDa), sodium lauryl 
sulfate, purified type II mucin and thiazolyl blue tetrazolium bromide 
were acquired from Sigma-Aldrich Química (Sintra, Portugal), PVA 
(57–66 kDa) from Alfa Aesar (Kandel, Germany), and 1,2-dimyristoyl- 
sn-glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phos-
phoethanolamine (DOPE) and cholesterol (CHL) from Avanti Polar 
Lipids (INstruchemie, Delfzyl, The Netherlands). Truvada® (Gilead 
Sciences, Lisbon, Portugal) was acquired from a local pharmacy. All 
other reagents and solvents were of analytical grade or equivalent. 
2.2. Preparation and characterization of liposomes 
Liposomes were prepared using the thin film hydration technique by 
modifying a previously reported method [24]. Briefly, DMPC, DOPE and 
CHL at a molar ratio of 7:2:1 were dissolved in chloroform and the 
resulting solution was evaporated at 37 ◦C under a constant stream of 
nitrogen. The obtained film was hydrated with ultrapure water above 
the lipid main phase transition temperature and containing 40 μM of 
TDF and 28 μM of FTC. The lipid suspension was vortexed to produce 
liposomes with a final concentration of 4 mM, which were then soni-
cated in an ultrasonic bath for one minute. Liposomes were character-
ized for mean hydrodynamic diameter and zeta potential at 25 ◦C using a 
Zetasizer Nano ZS (Malvern Panalytical, Malvern, UK). 
2.3. Production of fibers 
PCL-based fibers containing TDF/FTC (further referred to as ‘PCL 
fibers’) and PVA-based fibers incorporating TDF/FTC-loaded liposomes 
(further referred to as ‘liposomes-in-PVA fibers’) were produced by 
electrospinning. Both polymers were dissolved in suitable solvent sys-
tems to a final concentration of 7–10% (w/v). A mixture of chloroform 
and methanol (3:2 in volume) at room temperature was used for PCL, 
while PVA was dissolved in an aqueous dispersion of liposomes at 80 ◦C. 
TDF and FTC (or drug-loaded liposomes) were then added to a final 
concentration of 4.0% (w/w) and 2.8% (w/w), respectively. An in-house 
electrospinning setup composed by a CZE2000 high voltage power 
supply (Spellman, Hauppauge, NY, USA), a 5 mL plastic syringe coupled 
to a blunt-end 22G (PCL fibers) or 19G (PVA fibers) needle, a single 
syringe pump (KD Scientific, Holliston, MA, USA), and a grounded drum 
collector rotating at 100 rpm was used to produce fibers. Precursor so-
lutions were pumped at 0.6 mL⋅h− 1 (PCL) or 0.1 mL⋅h− 1 (PVA) in the 
presence of a 15 kV (PCL fibers) or 20 kV (PVA fibers) electrical field and 
collected at a distance of 11 cm. Resulting fiber mats were dried and 
maintained in a vacuum desiccator until used. PCL fibers and liposomes- 
in-PVA fibers without drugs, as well as PVA fibers without liposomes and 
drugs, were similarly obtained by omitting drug and/or liposome 
incorporation during production. 
2.4. Physicochemical, mechanical and biopharmaceutical 
characterization of fibers 
The morphology of fibers was analyzed by scanning electron mi-
croscopy (SEM) using a Nova NanoSEM 200 (FEI, Hillsboro, OR, USA) at 
an acceleration voltage of 15 kV. Cryogenic fractured samples were 
sputter coated with gold before analysis. Cross-section diameter values 
of fibers were determined from acquired images using the Digimizer® 
software (MedCalc Software, Ostend, Belgium). A minimum of 100 
measurements were performed for each fiber type. The apparent 
porosity percentage (P%) of fiber mats was estimated from thickness 
measurements according to the following equation: 
P% = 1 −
ρfibers
ρpolymer
× 100 (1)  
where ρpolymer is the density of PCL (1.15 g⋅cm− 3) or PVA (1.26 g⋅cm− 3) 
and ρfibers is the apparent density of fiber mats obtained by dividing the 
mass of a sample by its volume. 
Thermal transitions and thermodynamic parameters of the fibers 
were analyzed by differential scanning calorimetry (DSC). Measure-
ments were carried out under nitrogen atmosphere using a DSC 214 
Polyma (NETZSCH, Selb, Germany), as previously described [25]. 
Thermograms were obtained at a heating rate of 10 ◦C⋅min− 1 in the 
range of 0–100 ◦C for PCL fibers and 150–250 ◦C for liposomes-in-PVA 
fibers. Thermodynamic parameters were calculated using the Proteus® 
7.1 software (NETZSCH). 
X-ray diffraction patterns were acquired with the micro-focus wide- 
R. Nunes et al.                                                                                                                                                                                                                                   
Journal of Controlled Release 334 (2021) 453–462
455
angle X-ray scattering beam line (MiNaXS) of PETRA III (DESY, 
Hamburg, Germany) using monochromatic synchrotron X-ray radiation 
(energy of approximately 15 keV and wavelength in the range of 0.82 
Å). To observe the complete scattering pattern, a 2D pixel detector 
PILATUS 1M (Dectris, Baden-Daettwil, Switzerland) was used, with a 
pixel size of (172 × 172) μm2. 
The mechanical properties of fiber mats were studied using an AG-IS 
universal testing machine (Shimadzu, Kyoto, Japan). Stress-strain tests 
were carried out with a 10 N load cell and a deformation speed of 10 
mm⋅min− 1 until rupture of fiber mat samples (10 mm in width and 25 
mm in length). Young’s modulus (E) was estimated by linear fitting of 
stress-strain profiles for 0–7% of maximum stress. 
Mucoadhesive potential of fibers was assessed by estimating their 
quenching effect on the intrinsic fluorescence of mucin [24]. Fiber mat 
samples were immersed in an aqueous mucin dispersion (0.2 mg⋅mL− 1) 
for 180 min at 37 ◦C and 100 rpm. Fluorescence measurements of the 
mucin suspension before and after contact with fibers were carried out 
at excitation/emission wavelengths of 270 nm/300–500 nm using a LS 
50B fluorimeter (Perkin Elmer, Waltham, MA, USA). 
In vitro release of TDF and FTC from fibers was assessed in lactate 
buffer (pH 4.5) containing 12 mM sodium lauryl sulfate (micellar me-
dium) in order to allow establishing sink conditions while mimicking the 
amphiphilic content of the cervicovaginal fluids [26]. Briefly, fiber 
samples (3 × 2 cm) were immersed in 30 mL of medium and maintained 
at 37 ◦C under shaking conditions (120 rpm). Medium samples (1 mL) 
were collected at pre-determined time points and replaced with fresh 
medium, before being assayed by a UV/Vis spectrophotometric deriva-
tive method in the range of 200–400 nm [27]. In vitro drug release 
profiles were fitted to commonly used kinetics models (first order, 
Korsmeyer-Peppas and Gallagher-Corrigan) using Prism® 5 software 
(GraphPad Software, La Jolla, CA, USA). 
Cytotoxicity of fibers to two female genital cell lines was assessed 
using the MTT metabolic activity assay, as previously described [28]. Ca 
Ski cervical and HEC-1-A endometrial cells (ATCC, Manassas, VA, USA), 
were maintained in RPMI 1640 medium or McCoy’s 5A modified me-
dium, respectively, supplemented in both cases with 10% (v/v) fetal 
bovine serum (Biochrom GmbH, Berlin, Germany), 100 U⋅mL− 1 peni-
cillin and 100 μg⋅mL− 1 streptomycin (BioWest, Nuaillé, France) under 
standard conditions (37 ◦C, 5% CO2 and 95% RH). Extracts were pre-
pared by immersing fiber samples in culture medium at a mat surface 
area-to-volume of medium of 1 cm2⋅mL− 1 during 24 h at 37 ◦C. Extracts 
were added to cells (104 per well pre-incubated for 24 h in 96-well 
plates) and allowed to incubate for 24 h. Cells were then washed 
twice with phosphate buffered saline (pH 7.4) before adding MTT at 0.5 
mg⋅mL− 1 in medium and incubating for 4 h under standard conditions. 
Formazan crystals were dissolved with DMSO and cell viability was 
determined by measuring the absorbance at 570 nm. Extracts of 1% (w/ 
v) Triton® X-100 and plain media were used as controls. Also, extracts of 
a commercial contraceptive film containing 28% nonoxynol-9 (VCF® 
Vaginal Contraceptive Film, Apothecus, Oyster Bay, NY, USA) were 
tested for comparison purposes. 
2.5. Pharmacokinetics of TDF/FTC-loaded fibers 
The concentrations of TDF, TFV and FTC in vaginal lavage and tissue, 
as well as blood plasma, were determined between 15 min and 24 h after 
either intravaginal administration of fibers containing TDF/FTC or oral 
administration of the drug combinations to 8–12 weeks old female ICR 
mice. All procedures and experiments were performed using mice bred 
at the i3S animal facility, approved by the Ethics Committee at IUCS- 
CESPU (process no. 01/ORBEACESPU/2014) and conducted under the 
European Directive 2010/63/EU guidance, as previously detailed 
[29,30]. Mice were pre-treated subcutaneously with 3 mg of medrox-
yprogesterone (Depo-Provera®, Pfizer, Porto Salvo, Portugal) at seven 
and three days before administration of TDF/FTC in order to induce a 
diestrus-like state. Square-shaped fiber mats with approximately 20–25 
mm2 and containing of 0.07 mg of TDF and 0.05 mg of FTC were folded 
in half and administered intravaginally to conscious animals with the 
aid of tweezers [30]. Oral gavage of TDF/FTC to conscious mice was 
conducted after pulverization and dispersion of Truvada® tablets in 
water. Five daily administrations of TDF (62 mg⋅kg− 1) and FTC (41 
mg⋅kg− 1) were performed. Animals were allowed to move freely 
throughout all experiments, with free access to water and food. 
After a single intravaginal administration of fibers or following the 
fifth oral administration of TDF/FTC, mice were euthanized at pre- 
determined time points (15 min, 1 h, 4 h and 24 h) by inhalational 
isoflurane overdose, followed by intracardiac exsanguination. Blood was 
collected into Vacuette® tubes with K3EDTA (Greiner Bio-One, Krems-
münter, Austria) and plasma was recovered by centrifugation (1180 ×g, 
10 min) at 4 ◦C. The vagina was washed four times with 50 μL of normal 
saline using a micropipette, and the full recovered fluid centrifuged 
(13,414 ×g, 10 min) at 4 ◦C before collection of supernatant (lavage). 
Upon necropsy, the vagina was dissected and cut open along its longest 
axis. Visible residues of fibers were removed in the case of animals 
treated intravaginally before tissue collection. All samples (plasma, 
lavage and tissue) were stored at − 80 ◦C until further processing. Drug 
assay was conducted by liquid chromatography-tandem mass spec-
trometry (LC-MS/MS), as detailed in Supporting Information (S1. Sup-
porting Methods). Data were used to determine: (i) the maximum 
observed concentration (Cmax) and time at which it occurred (tmax); (ii) 
the area-under-the-curve between 15 min and 24 h (AUC0.25-24h), as 
calculated by the trapezoidal rule using Prism® 5 software; and (iii) the 
relative bioavailability (Frel), defined as the ratio between AUC0.25-24h 
values obtained for fibers and oral TDF/FTC, without dose adjustment. 
Groups of five animals were used per treatment and time point. 
2.6. Statistical analysis 
Experiments were performed in triplicate unless otherwise noted. 
Data are presented as mean ± standard deviation (SD), except in the case 
of PK results for which error is expressed as the standard error of the 
mean (s.e.m.). Multiple group comparisons were performed by one-way 
ANOVA with Tukey’s HSD post-hoc using Prism® 5 software. Values of 
p < 0.05 were assumed as denoting significant differences. 
3. Results and discussion 
3.1. Physicochemical and mechanical characterization of TDF/FTC- 
loaded fibers 
Both types of TDF/FTC-loaded fibers were successfully produced by 
electrospinning. Drug-loaded liposomes featuring diameter of 211 ± 24 
nm and zeta potential of − 0.67 ± 0.01 mV were incorporated into PVA 
fibers. Liposomes-in-PVA and PCL fibers weighted 2.32 ± 0.73 mg⋅cm− 2 
and 4.12 ± 0.23 mg⋅cm− 2, respectively. Drug content of liposomes-in- 
PVA fibers was 0.28 mg⋅cm− 2 (or 0.12 mg⋅mg− 1 of fibers) in TDF and 
0.20 mg⋅cm− 2 (or 0.086 mg⋅mg− 1 of fibers) in FTC, while PCL fibers 
contained 0.34 mg⋅cm− 2 (or 0.083 mg⋅mg− 1 of fibers) of TDF and 0.24 
mg⋅cm− 2 (or 0.058 mg⋅mg− 1 of fibers) of FTC. PCL and liposomes-in- 
PVA fiber meshes were glossy or pale white, respectively, homoge-
neous, and soft to the touch (Supporting Information, Fig. S1). Thickness 
of PCL and liposomes-in-PVA fiber mats was 364 ± 2.74 μm and 133 ±
4.67 μm, respectively, while P% was similar in both cases and estimated 
at 88–90% (Supporting Information, Fig. S1). SEM imaging revealed that 
both types of fibers were continuous and had a smooth surface (Fig. 1A). 
Values for cross-section diameter of PCL fibers and liposomes-in-PVA 
fibers containing TDF and FTC were 726 ± 279 nm and 222 ± 86 nm, 
respectively. PCL fibers were not only thicker, but also more heteroge-
neous in size distribution (Fig. 1B). The incorporation of drugs and drug- 
loaded liposomes was shown to substantially modify the appearance of 
both types of fibers. PCL fibers without TDF and FTC were roughly 20% 
thinner (591 ± 191 nm) than drug-loaded counterparts (Supporting 
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Information, Fig. S2). PCL (logP = 4.03) is highly lipophilic and unable to 
dissolve moderately lipophilic/hydrophilic drugs, such as TDF (logP =
1.25) and FTC (logP = − 0.43). This may dictate the disruption of PCL 
crystalline domains with consequent fiber enlargement. Conversely, 
PVA without TDF/FTC-loaded liposomes featured larger a cross-section 
diameter value of 460 ± 118 nm (Supporting Information, Fig. S2). PVA 
(logP = 0.26) is not only able to molecularly disperse TDF and FTC, but 
the incorporation of liposomes may also have led to better polymeric 
alignment and consequent decrease in fiber diameter. Interestingly, 
drug-loaded liposomes-in-PVA fibers featured distinctive points of 
enlargement (roundish bulges), possibly due to the presence of 
agglomerated liposomes (Fig. 1A). This effect has been previously re-
ported by others [31] and was particularly noticeable in the case of 
liposomes-in-PVA fibers without drugs (Supporting Information, Fig. S2). 
The reduced amount of enlarged points in drug-loaded liposomes-in- 
PVA fibers may be related to the ability of the active compounds 
(especially FTC) to disturb lipid packing [24], thus making liposomes 
possibly more flexible and featuring less roundish bulges. 
DSC analysis was conducted in order to infer the compatibility of 
fiber ingredients and to analyze the effect of drugs/liposomes on fiber 
structure. Thermograms underscore the dominance of PCL or PVA, 
namely by featuring single endothermal peaks resulting from polymer 
fusion (Fig. 1C). Melting temperature (Tm) values and correspondent 
enthalpy change (ΔH) are presented in Table 1 and overlap typical 
values for PCL or PVA [32,33]. Still, mild reduction of Tm and ΔH were 
observed for PCL-based fibers upon drug incorporation, corresponding 
to a 5% loss in crystallinity. This suggests lesser fiber stiffness when 
drugs are present, which is consistent with the different lipophilicity of 
drugs and polymer. Thermograms of liposomes-in-PVA fibers did not 
feature typical melting endotherms of drugs (TDF at 115 ◦C [34] and 
FTC 180 ◦C [35]) or lipids, thus suggesting good miscibility/incorpo-
ration of drugs and liposomes in the polymeric matrix. However, a small 
reduction in Tm was observed upon drug/liposome addition, which was 
accompanied by a marked increase in the crystallinity of the polymeric 
matrix. This appears to indicate that liposomes favored the homoge-
neous distribution of drugs in PVA fibers, as well as their compatibility. 
We next tested fibers by X-ray diffraction in order to confirm 
crystallinity changes inferred from DSC data. Diffractograms are shown 
in Fig. 1D. PCL fibers featured two diffraction peaks at 2θ = 21.4◦ and 2θ 
= 23.8◦ corresponding to the reflections according to the planes 
(110,200), respectively [36,37]. Both are indicative of the distinctive 
orthorhombic crystal lattice of the polymer, being only slightly 
decreased when TDF/FTC were incorporated. This mild loss of the 
crystallinity of PCL is in agreement with DSC results. In the case of PVA- 
based fibers, diffractograms were dominated by a characteristic peak at 
2θ = 19.3◦ [38]. The higher intensity of this peak after the incorporation 
of TDF/FTC-loaded liposomes supports an increase in crystallinity of 
fibers and confirms DSC results. 
Changes in crystallinity due the incorporation of drugs/liposomes 
are deemed acceptable as long as they do not compromise the me-
chanical resistance and structural integrity of mats. Therefore, we per-
formed uniaxial tensile tests (Fig. 1E) and calculated parameters such as 
elongation (ε) and tensile strength (TSmax) at break, as well as elastic 
Fig. 1. Physicochemical and mechanical properties of TDF/FTC-loaded fibers. (A) Representative SEM images (insets highlight discrete points of enlargement along 
liposomes-in-PVA fibers). (B) Cross-section diameter distribution. (C) DSC thermograms and (D) X-ray diffractograms of fibers with or without the incorporation of 
drugs/drug-loaded liposomes. PVA fibers (no drugs) denotes plain fibers obtained without the incorporation of any drug or liposomes. (E) Representative stress- 
strain curves. 
Table 1 
Thermodynamic parameters and mechanical properties of fibers, as evaluated 
by DSC and tensile stress tests. Results for mechanical properties are presented as 
mean ± SD (n = 3).  
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drugs) 
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Tm – melting point temperature; ΔH – enthalpic variation; ΔCrys – variation of 
crystalline structure (calculated as ΔCrys = 100 × ΔHfibers with drugs / ΔHfibers 
without drugs); TSmax – Maximum tensile strength at break; ε - elongation at break; 
E – Young’s modulus. (a) PVA fibers (no drugs) denotes plain fibers obtained 
without the incorporation of any drug or liposomes. 
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modulus (Young’s modulus; E), in order to evaluate the mechanical 
properties of fibers. Considerable differences were observed when 
drugs/liposomes were present or not (Table 1 and Supporting Informa-
tion, Fig. S3). Variations in crystallinity were positively correlated with 
values of E for both types of fibers. PCL fiber mats containing drugs 
demonstrated a reasonable balance between flexibility and hardness, 
being able to withstand over 50% extensional strain. PVA-based fiber 
mats were less flexible (lower ε values) than PCL fibers, but the incor-
poration of TDF/FTC-loaded liposomes did not affect this feature. From 
a practical point of view, both types of fiber mats could be considered as 
resistant to relevant handling (e.g., occurring during manufacturing, 
transport or administration), namely when compared to vaginal films 
designed for use as microbicides (E = 5.4–7.8 MPa [39]). 
3.2. Biopharmaceutical properties of TDF/FTC-loaded fibers 
The ability of a drug delivery system to associate with mucin at the 
nanoscale provides a valuable indicator of its putative mucoadhesive 
properties [40]. We assessed the capacity of fibers to quench the 
intrinsic fluorescence of mucin by establishing hydrophobic interactions 
with tryptophan residues. PCL-based fibers were able to reduce fluo-
rescence intensity (Fig. 2A), thus suggesting strong binding to mucin. 
The quenching effect was particularly pronounced for fibers containing 
TDF/FTC, which was related to the ability of drugs themselves to 
interact with tryptophan (Supporting Information, Fig. S4). Additional 
SEM imaging indicated that mucin was able to intimately coat PCL- 
based fibers, while X-ray diffraction experiments showed decreased in-
tensity in typical peaks of this type of fibers when mucin was present 
(Supporting Information, Fig. S4). Altogether, these results suggest that 
PCL fibers are mucoadhesive due to hydrophobic bonding to mucin 
[41,42]. Conversely, liposomes-in-PVA fibers did not appear to interact 
with mucin, except when TDF/FTC were included (Fig. 2A). Results 
from fluorescence quenching experiments were further reinforced by 
results of X-ray diffraction patterns for PVA-based fibers in the presence 
or absence of mucin (Supporting Information, Fig. S4). This seems to 
indicate that PVA-based fibers feature low mucoadhesiveness, in 
apparent contrast with previous literature indicating that the polymer is 
considered to possess mild mucoadhesiveness [43,44]. Curiously, its use 
in vaginal film formulations is frequent, but usually in combination with 
polymers possessing higher mucoadhesive potential [45]. Previous 
studies testing PVA-based fibers also indicate that this polymer seems to 
possess relatively low in vitro and in vivo mucoadhesiveness upon elec-
trospinning [46,47]. The ability of PVA to interact with mucin is 
dependent on physicochemical properties and processing, namely on the 
presence of hydrophobic vinyl acetate units. In fact, PVA presenting 
higher degree of hydrolysis (75–94%) – such as the one used in the 
present study – has been shown to present decreased mucoadhesiveness 
[48]. We also hypothesize that the availability of vinyl acetate units at 
the surface of fibers may have also been altered due to possible orien-
tation of such hydrophobic residues towards the inner core of the sys-
tem, preferentially leaving hydrolyzed fractions of PVA at the interface. 
For example, this arrangement and fine-tuning of vinyl acetate/vinyl 
alcohol content has been shown effective in rendering sub-micrometer 
particles as mucus-diffusive in previous studies [48]. Overall, and 
assuming the quenching percentage as a quantitative indicator of 
mucoadhesiveness, PCL fibers were approximately 10-fold more 
mucoadhesive than liposomes-in-PVA fibers (Supporting Information, 
Fig. S5). These results, however, should be interpreted with caution. 
Quenching of the intrinsic fluorescence of mucin mostly assesses hy-
drophobic interactions [49], which have been estimated as quite rele-
vant in defining the mucoadhesiveness of vaginal formulations [50]. 
Nevertheless, other types of interactions (e.g., electrostatic and 
hydrogen bonding) that are important in defining the adhesiveness of 
hydrophilic polymers may have been underestimated. 
Next, we evaluated the ability of fibers to release TDF and FTC in 
micellar medium at pH 4.5. Drug release from PCL fibers was fast 
Fig. 2. Biopharmaceutical properties of TDF/FTC-loaded fibers. (A) Fluorescence emission spectra of mucin before and after incubation with fibers. PVA fibers (no 
drugs) denotes plain fibers obtained without the incorporation of any drug or liposomes. (B) Cumulative drug release-time profiles of drugs from fibers in micellar 
medium (pH 4.5) at 37 ◦C. (C) Viability of Ca Ski and HEC-1-A cells upon incubation with fibers (with or without the incorporation of drugs/drug-loaded liposomes). 
Results in (B) and (C) are presented as mean ± SD (n = 3). 
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(within 15–30 min), even if roughly half the amount of FTC was retained 
up to at least 4 h (Fig. 2B). While the rapid and complete release of TDF 
suggests that this drug is located mostly at the surface of the system, the 
profile of FTC points to a more homogeneous distribution within the PCL 
matrix [51]. Previous studies showed that TDF typically presents burst 
release from electrospun fibers composed of hydrophobic polymers such 
as (poly(lactic-co-glycolic acid) (PLGA), poly(lactide-co-caprolactone), 
or a 20:80 blend of PCL and PLGA [19,51]. Noticeably, the apparent 
decrease trend observed in the release profile of TDF from PCL fibers up 
to 4 h was likely related with the hydrolysis of the two iso-
propyloxycarbonyloxymethyl groups of this prodrug in aqueous media, 
as previously described by Carson and co-workers [19]. Liposomes-in- 
PVA fibers presented similar release profiles to PCL fibers, although 
the amount of retained FTC was lower (approximately 25%). This 
fraction of FTC is likely intimately associated with liposomes as PVA- 
based fibers are highly soluble and prone to rapidly release payloads. 
The use of liposomes also seemed to enhance the resistance of TDF to 
hydrolysis throughout the assay, as apparent for PCL fibers or when the 
prodrug was directly incorporated into PVA fibers without using lipo-
somes (data not shown). Release profiles of both types of fibers were best 
fitted to the Gallagher-Corrigan model (R2adjusted ≥ 0.979; Supporting 
Information, Tables S1 and S2), which is indicative of typical biphasic 
behavior (initial burst followed by slow release) of biodegradable 
polymeric system [52]. Overall, rapid drug release observed for PCL 
fibers and liposomes-in-PVA fibers may be considered as beneficial for 
developing on-demand microbicides, since pericoital administration 
requires that protective levels of TDF and FTC are achieved in a very 
short amount of time. Although not explored, fibers developed in this 
work may still be useful for developing sustained release products, 
namely by stacking drug-loaded and non-medicated sheets of fiber, as 
previously proposed by other researchers [53,54]. 
Lastly, we assessed the toxicity potential of fibers using well- 
established in vitro genital cell models. Extracts of fibers were shown 
not to be cytotoxic (Fig. 2C). Cell viability was maintained above 90% 
for PCL fibers and liposomes-in-PVA fibers – well above the 70% 
threshold that is usually considered when testing biomedical materials 
and devices [55] –,contrasting with the results for VCF® film extracts. 
These data are in agreement with the recognized safety of PCL and PVA, 
as well as the relatively low toxicity potential of TDF and FTC. For 
instance, the maximum concentrations achievable for TDF and FTC in 
fiber extracts were 140 μg⋅mL− 1 and 100 μg⋅mL− 1, respectively, which 
are below the half-maximal cytotoxic concentration (CC50) values 
determined for these drugs in the HeLa cervical cell line (231 μg⋅mL− 1 
and > 300 μg⋅mL− 1, respectively) [28]. 
3.3. Pharmacokinetics of TDF/FTC-loaded fibers 
We conducted in vivo experiments in a non-infectious animal model 
in order to compare local and systemic PK of intravaginally adminis-
tered fibers with oral TDF/FTC. The vaginal doses of TDF (0.07 mg) and 
FTC (0.05 mg) were selected in accordance with previous studies 
demonstrating efficacy in preventing vaginal HIV-1 transmission in 
humanized mice [12,15]. These doses corresponded to the administra-
tion of mats with 20 mm2 (5 mm × 4 mm) for PCL fibers and 25 mm2 (5 
mm × 5 mm) for liposomes-in-PVA fibers. Truvada® was used in order 
to better mimic real-world usage of TDF/FTC. Tablets can be crushed 
and dispersed in water immediately before intake without affecting PK 
according to information included in the ‘Summary of Product Charac-
teristics’. TDF/FTC was administered by gavage at 61.5 mg of TDF and 
41 mg of FTC per kg of body weight (animals weighing about 30 g), 
which correspond to roughly 25-times the doses administered intra-
vaginally. These were selected by considering the human doses for oral 
PrEP and back-calculating the amount of each drug for mice using 
allometric scaling, as defined by the FDA [56]. While the PK of fibers 
were assessed after a single dose, five daily doses were administered to 
mice in order to simulate continuous oral PrEP and achieve steady-state 
drug levels [57]. 
Drug concentrations – including those of TFV resulting from the 
hydrolysis of TDF – were determined in vaginal lavage and tissue, as well 
as in blood plasma, and are presented in Fig. 3. Sampling times were 15 
min, 1 h, 4 h and 24 h post-administration, which allow assessing 
representative short-term, medium-term, long-term and terminal levels 
of topical microbicides in mice [29,30]. Results for vaginal lavage 
(Fig. 3A) showed that concentrations of TDF, TFV and FTC were 
generally higher for liposomes-in-PVA fibers as compared to oral PrEP, 
particularly at earlier time points, which suggests that these fibers could 
rapidly provide protective levels upon a single administration. Differ-
ences between liposomes-in-PVA fibers and oral TDF/FTC can even be 
better assessed by comparing values of AUC0.25-24h (Table 2). For 
instance, TFV and FTC levels were roughly 4- and 29-times higher, 
respectively. Differences were also significant for TDF, for which no 
detectable levels were registered for oral administration. PCL fibers also 
allowed achieving higher drug concentrations than oral TDF/FTC, 
although differences were less pronounced. This could be attributable, 
at least in part, to the poor wettability of hydrophobic fibers and, hence, 
the inability of the PCL matrix to fully release drugs in the reduced 
amount of fluids present in the vagina of mice. Indeed, 4 and 3 animals 
(out of 5) still presented readily identifiable PCL fiber mats at 15 min 
and 1 h post-administration, respectively (Supporting Information, 
Tables S3). It should also be noted that both TDF and FTC present high 
enough intrinsic aqueous solubility to assure that the amounts admin-
istered to the animals may dissolve in the expectable low amount of 
mucus present in the vagina [58]. The amount of non-released TDF and 
FTC could not be assayed since the quantitative collection of residual 
fibers was unfeasible during necropsy. The capacity of both fibers to 
allow achieving tangible vaginal levels of TDF (contrasting with non- 
detectable levels for oral treatment) are particularly relevant due to 
the enhanced capacity of the prodrug to yield intracellular levels of the 
active metabolite TFV diphosphate as compared to TFV [59]. Overall, 
the results for vaginal lavage seem to support that the administration of 
TDF/FTC-loaded fibers may be able to provide immediate protective 
concentrations of both drugs that are superior to oral TDF/FTC. 
While results for lavage were quite distinct, data analysis for vaginal 
tissue was hindered by considerable interindividual variability and 
generally low drug concentrations in samples (Fig. 3B). There was, 
however, a trend for higher drug levels in the case of oral TDF/FTC, 
which were significant at 1 h post-administration in the case of TDF and 
FTC. This suggests some degree of drug accumulation in tissue resulting 
from continuous oral use or simply poor mucosal permeation of intra-
vaginally administered drugs. TDF, TFV and FTC are BCS class III 
compounds and substrates of important efflux transporters such as P- 
glycoprotein (TDF and TFV), Mrp1 (FTC) or Mrp4 (TFV), which are 
highly expressed in the cervicovaginal mucosa of mice [60–62]. PK 
parameters further reinforce the reduced ability of fibers to yield lower 
drug concentrations in tissue (Table 2). This was particularly apparent 
for FTC (Frel = 0.02–0.2), while in the case of TFV or its prodrug, fibers 
could achieve similar levels of one of these compounds (Frel (TDF) = 0.9 
for liposomes-in-PVA fibers and Frel (TFV) = 0.5 for PCL fibers). Note-
worthy, TFV levels in vaginal tissue following oral administration were 
in general agreement with results reported for TDF administered orally 
to female BALB/c mice (AUC2-24h = 9681 ng⋅h⋅g− 1 and tmax between 2 h 
and 8 h) [57], with variations likely reflecting differences in sample 
collection time points. In the case of vaginal administration of TDF and 
FTC, no comparable regional PK data have been previously described. 
Data for blood plasma indicate low systemic drug exposure with the 
use of topical fibers, as denoted by their values of AUC0.25-24h and Frel 
(Table 2). It is worthwhile mentioning that one of the defining advan-
tages of microbicides over oral PrEP relates with the principle of 
blocking transmission at the mucosal site and abbreviate the onset of 
possible adverse effects related with high systemic exposure to active 
payloads [63]. The blood plasma profile obtained for TFV with oral 
TDF/FTC was consistent with data previously found for the oral 
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administration of TDF to female BALB/c mice, namely concerning the 
early onset of Cmax [57,64]. However, AUC values for similar oral doses 
were widely variable among studies: Veselinovic et al. [57] reported 
AUC2-48h = 17,278 ng⋅h⋅mL− 1 (12,251 ng⋅h⋅mL− 1 when tested in hu-
manized mice), while Ng et al. [64] reported AUC0.5-24h = 3984 
ng⋅h⋅mL− 1. Again, these variations probably reflect methodological 
differences between studies. 
Apart from the discussion regarding relative drug levels in different 
biological samples for considered administration routes and/or fibers, it 
seems important to infer on how absolute values could translate into 
protection from HIV-1 transmission. Correlation between regional PK 
and efficacy for topical TDF/FTC has not yet been fully established. 
However, data from Gallay et al. [15] suggest that vaginal lavage con-
centrations of at least 4 ng/mL for FTC and 500 ng/mL for TDF 
(assuming a washing protocol similar to the one used in this work) are 
associated with full prevention of viral transmission in humanized mice. 
In our study, mean levels of FTC in lavage between 15 min and 1 h post- 
administration were at least around 6000- and 250-times higher than 
the previous protective threshold in the case of liposomes-in-PVA fibers 
and PCL fibers, respectively. As for oral treatment, the concentration of 
FTC in lavage at 1 h was considerably above 4 ng/mL, but could not be 
guaranteed early on following administration. Mean levels of TDF in 
lavage were also maintained at least 2-times above the threshold re-
ported by Gallay et al. for liposomes-in-PVA fibers between 15 min and 
1 h. This was not the case for PCL fibers at 15 min. TDF in lavage was 
undetectable in the case of oral administration from 15 min to 24 h, 
which could reflect the conversion of the prodrug into TFV by esterases 
following oral absorption [65]. Furthermore, measurable plasmatic 
levels of TDF and TFV suggest that these drugs actually have poor ability 
to concentrate in the vaginal tissue of mice, thus paralleling what has 
been reported for women [9]. 
This study presents a few limitations that need to be considered when 
interpreting its findings. Firstly, PK data discussed in this manuscript 
reflect the analysis of a limited amount of time points that, nonetheless, 
typically reflect the dynamics of vaginal microbicide drug delivery in 
mice, as discussed above. Results from mouse models should also be 
interpreted carefully, particularly when envisioning a direct translation 
into the human scenario. Vaginal leakage in mice after topical admin-
istration is particularly extensive, and leads to low and rapidly 
decreasing drug levels. Still, the relevance of mouse models (namely 
humanized) to the development of PrEP cannot be denied and com-
parison with gold standard clinical practice, such as represented by oral 
Fig. 3. PK profiles of fibers and oral TDF/FTC. Time-dependent concentrations of TDF, TFV and FTC in different biological samples upon administration of vaginal 
fibers or oral TDF/FTC. Concentrations of drugs in (A) vaginal lavage, (B) vaginal tissue and (C) blood plasma are presented as mean ± s.e.m. (n = 5). (a) and (b) 
denote statistically significant differences (p < 0.05) when comparing with oral TDF/FTC or the other type of fibers, respectively. 
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administration of Truvada in this study, provides important hints 
regarding the potential of new preventative strategies [66]. Secondly, 
we did not evaluate tissue levels of active metabolites of TDF/TFV and 
FTC, namely TFV diphosphate and FCT triphosphate. However, pre-
clinical (from mice) and clinical data support that genital tract levels of 
precursor and active forms are fairly correlated, and that vaginal PK 
profiles of TDF/TFV and FTC can be used to assess the potential for 
protection against HIV-1 transmission [15,67]. Thirdly, the impact of 
sexual intercourse on PK was not considered despite being likely 
considerable. Fourth, the role of liposomes and their association with 
fibers in enhancing mucosal drug levels was not fully assessed in this 
work. However, our previous work pinpoints that the association of 
nanocarriers to polymeric platforms used for vaginal administration, 
namely rapid-dissolving films, potentiates the local drug retention and 
distribution [30]. In a related study, Krogstad et al. [47] reported that 
the incorporation of etravirine-loaded PLGA nanoparticles into PVA fi-
bers provided enhanced vaginal retention of both nanocarrier and the 
antiretroviral drug over 7 days. Although the outcome of using 
liposomes-in-PVA fibers was not so remarkable, higher drug levels in 
vaginal lavage as compared to PCL fibers could be attributed to a similar 
effect resulting from the administration of a nanocarrier-in-fiber com-
posite. Fourthly, our study was designed only for comparing topical fi-
bers with currently approved oral PrEP with TDF/FTC. Still, it should be 
acknowledged that other promising topical [14,68] and systemic 
[69–71] delivery technologies for PrEP are currently being evaluated, 
and future comparative assessment would be interesting. Finally, formal 
safety studies were not conducted. Still, the reduced cytotoxicity of fi-
bers, alongside the favorable safety track record of individual materials, 
seem to backup that PCL fibers and liposomes-in-PVA fibers are poten-
tially safe. 
4. Conclusions 
We produced and characterized two formulations based on poly-
meric fibers that could be useful for the vaginal delivery of TDF and FTC 
in the context of topical PrEP. PCL fibers and liposomes-in-PVA fibers 
were shown to possess adequate biopharmaceutical properties, namely 
drug release profiles compatible with on-demand microbicide use and 
low toxicity to cells of the female genital tract. Both types of fibers 
provided rapid onset of local drug levels upon single vaginal adminis-
tration to mice, namely when compared to the continuous daily use for 
five days of oral TDF/FTC. Moreover, drug concentrations in vaginal 
fluids were moderately sustained up to 1–4 h, which could be translat-
able into a fairly wide protection time window in humans. This was 
particularly noticeable for liposomes-in-PVA fibers. The ability of fibers 
to provide vaginal tissue drug concentrations that were at least as high 
as those obtained with oral TDF/FTC was not clear and needs further 
clarification. Overall, the proposed drug-loaded fibers may provide an 
interesting on-demand alternative or a complementary tool to currently 
available oral PrEP requiring the daily administration of TDF/FTC. 
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Table 2 
PK parameters for TDF, TFV and TDF in vaginal lavage (VL), vaginal tissue (VT) and blood plasma (BP) after vaginal administration of drug-loaded fibers or oral 
administration of TDF/FTC. Results for Cmax and tmax are presented as mean ± s.e.m. (n = 5).  
Drugs Formulation Cmax (ng⋅mL− 1)a tmax (h) AUC0.25-24h (ng⋅h⋅mL− 1)b Frel 
VL VT BP VL VT BP VL VT BP VL VT BP 
TDF Oral TDF/FTC ND 17.9 ± 3.6 5550 ± 1013 ND 1 1 0 142.9 11,392 – – – 
Vaginal PCL fibers 584 ± 103 ND 3848 ± 1435 1 ND 1 1096 ND 7216 ND ≈0 0.6 
Vaginal liposomes-in-PVA fibers 4488 ± 820 6.2 ± 0.7 1474 ± 230 0.25 24 1 3470 130.7 2763 ND 0.9 0.2 
TFV Oral TDF/FTC 205 ± 72 225 ± 197 326 ± 162 1 4 0.25 1763 2690 818 – – – 
– Vaginal PCL fibers 492 ± 64 135 ± 116 14.8 ± 4.0 1 24 1 3981 1415 26.8 2.3 0.5 0.03  
Vaginal liposomes-in-PVA fibers 6929 ± 1746 6.2 ± 0.7 7.4 ± 3.1 0.25 24 1 6979 130.7 13.9 4.0 0.05 0.02 
FTC Oral TDF/FTC 1115 ± 618 8301 ± 236 9475 ± 2646 1 4 0.25 2091 20,447 18,917 – – – 
Vaginal PCL fibers 8498 ± 3377 688 ± 220 ND 0.25 0.25 ND 5040 3670 ND 2.4 0.2 ≈0 
Vaginal liposomes-in-PVA fibers 44,793 ± 7944 314 ± 145 15.5 ± 15.5 0.25 0.25 1 61,564 325 29.1 29.4 0.02 0.002 
ND – not determined. 
a ng⋅g− 1 for VT. 
b ng⋅h⋅g− 1 for vaginal tissue. 
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